BKBaldeep Kumar

Baldeep Kumar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Baldeep Kumar has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Ajay Prakash

    Department of Pharmacology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India

    29 shared publications
  • Bikash Medhi

    Department of Pharmacology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India

    4 shared publications
  • Anurag Kuhad

    Pharmacology Research Laboratory University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Study, Panjab University Chandigarh 160014 India

    3 shared publications
  • Manish Modi

    Department of Neurology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India

    3 shared publications
  • Biman Saikia

    Department of Immunopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India

    2 shared publications
  • Kanwaljit Chopra

    Pharmacology Research Laboratory, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India

    2 shared publications

Latest Publications

  • A mechanistic approach to explore the neuroprotective potential of zonisamide in seizures

    by Baldeep Kumar, Bikash Medhi, Manish Modi, Biman Saikia, Savita Verma Attri, Ajay Patial

    Epilepsy, a disease of the brain, is one of the most common serious neurological conditions. It is associated with a group of processes which alter energy metabolism, interrupt cellular ionic homeostasis, cause receptor dysfunction, activate inflammatory cascade, alter neurotransmitter uptake and result in neuronal damage. The increasing knowledge and understanding about the basis of neuronal changes in epilepsy lead to investigate the mechanistic pathway of neuroprotective agents in epilepsy. With this background, the present study is designed to reveal the molecular and biochemical mechanisms involved in the neuroprotective potential of zonisamide in epilepsy.


  • Evaluation of Brain Pharmacokinetic and Neuropharmacodynamic Attributes of an Antiepileptic Drug, Lacosamide, in Hepatic and Renal Impairment: Preclinical Evidence

    by Baldeep Kumar, Manish Modi, Biman Saikia, Bikash Medhi

    The knowledge of pharmacokinetic and pharmacodynamic properties of antiepileptic drugs is helpful in optimizing drug therapy for epilepsy. This study was designed to evaluate the pharmacokinetic and pharmacodynamic properties of lacosamide in experimentally induced hepatic and renal impairment in seizure animals. Hepatic or renal impairment was induced by injection of carbon tetrachloride or diclofenac sodium, respectively. After induction, the animals were administered a single dose of lacosamide. At different time points, maximal electroshock (MES) seizure recordings were made followed by isolation of plasma and brain samples for drug quantification and pharmacodynamic measurements. Our results showed a significant increase in the area under the curve of lacosamide in hepatic and renal impairment groups. Reduced clearance of lacosamide was observed in animals with renal impairment. Along with pharmacokinetic alterations, the changes in pharmacodynamic effects of lacosamide were also observed in all the groups. Lacosamide showed a significant protection against MES-induced seizures, oxidative stress, and neuroinflammatory cytokines. These findings revealed that experimentally induced hepatic or renal impairment could alter the pharmacokinetic as well as pharmacodynamic properties of lacosamide. Hence, these conditions may affect the safety and efficacy of lacosamide.


  • Novel Strategies for Effective Actinic Keratosis Treatment: A Review

    by Sudhir Kumar, Rakesh Kumar, Bikash Medhi, Vivek R. Sinha

    Actinic keratoses (AKs) are common premalignant skin lesions. These are epidermal neoplasms of altered keratinocytes. Development of Actinic keratosis is correlated with chronic exposure of UVB sun radiation resulting in formation of cyclobutane pyrimidine dimmers (CPDs). During UV exposure, expression of tumor suppressor gene p53 is enhanced, which protects and repairs damaged DNA, failing which, cell leads to apoptosis. An irreversible damage to p53 gene results in failure of apoptosis and DNA repair resulting in expansion of cells into neoplasm. Risk of progression of these actinic keratosis lesions to squamous cell carcinoma makes it necessary to treat them aggressively. Various modalities like, lesion directed therapy (cryosurgery, curettage and electrodessication) and field directed therapy (5-fluorouracil, diclofenac, imiquimod, photodynamic therapy etc) exists for its treatment. US Food and Drug Administration has approved 5 medications for AK treatment which are topical 5-Fluorouracil, imiquimod cream, diclofenac gel, ingenol mebutate gel and photodynamic therapy. To enhance the outcome of available treatment strategies, their combination are gaining popularity and interests of dermatologists because of their efficacy and tolerability. Fluorouracil and salicylic acid Actikerall® combination is such an example which has received marketing approval from Medicines and Healthcare Products Regulatory Agency in UK for AK treatment. This combination therapy approach is supposed to be another step towards the ultimate goal of enhancing the effectiveness of skin cancer treatments and reducing the number of surgical excisions performed on the millions of people with these precancerous skin lesions.

  • Potential of metabolomics in preclinical and clinical drug development

    by Baldeep Kumar, Ajay Prakash, Rakesh Kumar Ruhela, Bikash Medhi

    Metabolomics is an upcoming technology system which involves detailed experimental analysis of metabolic profiles. Due to its diverse applications in preclinical and clinical research, it became an useful tool for the drug discovery and drug development process. This review covers the brief outline about the instrumentation and interpretation of metabolic profiles. The applications of metabolomics have a considerable scope in the pharmaceutical industry, almost at each step from drug discovery to clinical development. These include finding drug target, potential safety and efficacy biomarkers and mechanisms of drug action, the validation of preclinical experimental models against human disease profiles, and the discovery of clinical safety and efficacy biomarkers. As we all know, nowadays the drug discovery and development process is a very expensive, and risky business. Failures at any stage of drug discovery and development process cost millions of dollars to the companies. Some of these failures or the associated risks could be prevented or minimized if there were better ways of drug screening, drug toxicity profiling and monitoring adverse drug reactions. Metabolomics potentially offers an effective route to address all the issues associated with the drug discovery and development.


  • Open Access

    A prospective study to evaluate awareness about medication errors amongst health-care personnel representing North, East, West Regions of India

    by Bikash Medhi, RakeshK Sewal, PawanK Singh, Ajay Prakash, Baldeep Kumar

    Background: Medication errors are prevalent in the hospital settings. To ensure the patient safety and provide better health services, medication errors should be curbed. India is still lacking the regulatory system for the control of medication errors. Therefore, a stringent regulatory set up should be established to reduce medication errors. Awareness among the health-care professionals regarding medication errors may be the major factor in the establishment of successful regulatory system. In Indian context, no study has been reported about the awareness of medication errors. Therefore, this study assessed the awareness of the health-care professionals representing North, East and West regions of India about medication errors. These health-care professionals also included the students who were in the final phase of professional courses related to health management. Materials and Methods: A questionnaire comprising of 17 questions pertaining to different aspects of medication errors was prepared. Questionnaire was distributed to 456 health-care professionals of various institutes of North, East and West India. Respondents of the questionnaire were restricted to one sitting for answering the entire questionnaire and they were not allowed to consult with anyone for the purpose of answering the questions. Data was compiled and analyzed. Results: It has been found that 18.45%, 39.48%, 14.16%, 27.9% of respondents were having excellent, good, average, poor knowledge respectively regarding the fundamentals of medication error. Knowledge regarding reporting medication errors was excellent in 56.65%, good in 22.53%, average in 09.23% and poor in 11.59% of respondents. Conclusion: The outcome of this study may be of great help in drafting the regulatory policies to curb the problem of medication errors.


  • Drug therapy in autism: a present and future perspective

    by Baldeep Kumar, Ajay Prakash, Rakesh K. Sewal, Bikash Medhi, Manish Modi

    Autism is a neurodevelopmental disorder, with a multifactorial etiology, characterized by severe abnormalities in communications, social awareness and skills, and the presence of restrictive and stereotyped patterns of behaviors. It is traditionally considered a "static" encephalopathic disorder without any specific cure and few effective biomedical interventions. There are various factors which are involved in the etiopathogenesis of autism or autism spectrum disorder (ASD) such as impaired immune responses, neuroinflammation, abnormal neurotransmission, oxidative stress, mitochondrial dysfunction, environmental toxins and stressors. The autism is often associated with a number of genetic disorders such as fragile X syndrome, tuberous sclerosis, epilepsy and Down syndrome. The recent approaches to autism treatment included various non-pharmacological and pharmacological therapy such as food supplementation, detoxification, treatment of neuroinflammation, immunologic treatments and psychotropic medications, which are found to be effective in treating various behavioral symptoms of autism. In current practice, there is no curative treatment for autism but the recommended treatment for autism involves educational therapies: speech therapy, sensory integration therapy, auditory therapy. There are classes of different pharmacological agents which are found to be effective in improving behavioral symptoms of ASD such as neurotransmitter reuptake inhibitors (fluoxetine), tricyclic antidepressants (imipramine), anticonvulsants (lamotrigine), atypical antipsychotics (clozapine), acetylcholinesterase inhibitors (rivastigmine), etc. New classes of drugs with novel mechanisms of action should be there so that this disorder will become less prevalent in the future.


  • Vaccinium myrtillus Ameliorates Unpredictable Chronic Mild Stress Induced Depression: Possible Involvement of Nitric Oxide Pathway

    by Baldeep Kumar, Vipin Arora, Anurag Kuhad, Kanwaljit Chopra

    Chronic unpredictable stressors can produce a situation similar to clinical depression and such animal models can be used for the preclinical evaluation of antidepressants. Nitric oxide, a secondary messenger molecule, has been implicated in neurotransmission, synaptic plasticity, learning, aggression and depression. Vaccinium myrtillus (bilberry) extract is a potent inhibitor of reactive oxygen/nitrogen species and cytokine production. The present study investigated the role of nitric oxide in the antidepressant action of Vaccinium myrtillus in unpredictable chronic mild stress-induced depression in mice. Animals were subjected to different stress paradigms daily for a period of 21 days to induce depressive-like behavior. Pretreatment with L-arginine significantly reversed the protective effect of bilberry (500 mg/kg) on chronic stress-induced behavioral (immobility period, sucrose preference) and biochemical (lipid peroxidation and nitrite levels; endogenous antioxidant activities) in stressed mice. Furthermore, L-NAME (10 mg/kg) pretreatment with a sub-effective dose of bilberry (250 mg/kg) significantly potentiated the protective effect of bilberry extract. The study revealed that modulation of the nitric oxide pathway might be involved in antidepressant-like effects of Vaccinium myrtillus in stressed mice.


  • Pathobiological targets of depression

    by Kanwaljit Chopra, Baldeep Kumar, Anurag Kuhad

    Depression is one of the most prevalent and life-threatening forms of mental illness associated with significant disability and mortality. About 21% of the world's population is affected by depression. The various pathological factors involved in depression are: monoamine hypothesis, neurotransmitter receptor hypothesis, neurotrophic factor hypothesis, hypothalamic-pituitary-adrenal (HPA) dysregulation, oxidative stress, cytokine hypothesis and NO pathway. Recent drug therapies used to treat depression include: selective serotonin re-uptake inhibitors, norepinephrine and dopamine re-uptake inhibitors and several herbal drugs. The present review focuses on recently unraveled pathogenetic hypotheses and therapeutics of mental depression. Moreover, various evaluation models for antidepressants are discussed. Stress can be considered as a major contributor to the development of depressive disorder due to the dysregulation of HPA axis. Cytokine effects on behavior are believed to be related in part to their effects on neurotransmitter and neuropeptide function, synaptic plasticity and neuroendocrine function. Although there are multiple pathways that are involved in the pathogenesis of depression, the current antidepressants mainly target monoaminergic pathway. However, the therapeutic potential of other pathways is still under investigation. Drugs targeting NO, cytokines and the kynurenine acid pathway might be the drugs of choice in near future.


  • Neuropsychopharmacological effect of sesamol in unpredictable chronic mild stress model of depression: behavioral and biochemical evidences

    by Baldeep Kumar, Anurag Kuhad, Kanwaljit Chopra

    A complex relationship exists among stressful situations, body's reaction to stress, and the onset of clinical depression. Chronic unpredictable stressors can produce a situation similar to clinical depression, and such animal models can be used for the preclinical evaluation of antidepressants. Many findings have shown that the levels of proinflammatory cytokines (e.g., TNF-α) and oxidative stress (increased lipid peroxidation, decreased glutathione levels, and endogenous antioxidant enzyme activities) are increased in patients with depression. Sesamol, a phenolic derivative with a methylenedioxy group, is a potent inhibitor of cytokine production as well as an antioxidant.